NextCell Pharma
1,75
SEK
-3,31 %
NXTCL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 investorer følger denne virksomhed
-3,31%
0%
+38,89%
+23,24%
-15,76%
-24,9%
-71,85%
-43,6%
-20,86%
www.nextcellpharma.com/investerare
NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.
Omsætning
10,66 mio.
EBIT %
-404,97 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
NXTCL
Daglig lav / høj pris
1,75 / 1,77
SEK
Markedsværdi
127,91 mio. SEK
Aktieomsætning
3,17 t SEK
Volumen
1,8 t
Finanskalender
Delårsrapport
30.01.2025
Delårsrapport
25.04.2025
Delårsrapport
24.07.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 15,6 % | 15,6 % |
| Diamyd Medical AB | 7,2 % | 7,2 % |
| Ålandsbanken | 3,9 % | 3,9 % |
| Nordnet Pensionsförsäkring | 3,3 % | 3,3 % |
| Pabros AB | 2,4 % | 2,4 % |
| Anders Essen-Möller | 2,2 % | 2,2 % |
| Martin Larsen | 2,2 % | 2,2 % |
| Nordea Livförsäkring Sverige AB | 1,7 % | 1,7 % |
| Clearstream Banking | 1,6 % | 1,6 % |
| Filip Wirefors | 1,5 % | 1,5 % |
ViserAlle indholdstyper
NextCell Pharma AB: QVance Announces Partnership
NextCell Pharma AB: QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools